Avandia has taken some beatings over the years, but it pretty much took a fatal blow yesterday. That's when the Food and Drug Administration ruled to keep the drug on the market in the United States with some serious restrictions.
Edward Darden started taking the diabetes drug Avandia in 2006 to help control his blood sugar and was doing just fine, he said. But he became concerned when he saw warnings linking the drug to a 43 percent increased risk of heart attack, following the 2007 release of a study in the New England Journal of Medicine.
CNN's Dr. Sanjay Gupta explains the controversy behind the diabetes drug Avandia.
GlaxoSmithKline is on the hook for Avandia, a drug that helps diabetes patients regulate blood sugar levels, but also causes heart problems. Critical reviews in major medical journals have repeatedly challenged its safety, and mainstream media have picked up on the studies in scathing articles. GSK has tried to defend the drug from the attacks, but there's only so much the company can do.
FDA officials will decide the ultimate fate of the diabetes drug Avandia. CNN's Dr. Sanjay Gupta reports.
A Food and Drug Administration committee delivered a split verdict on the diabetes drug Avandia on Wednesday, with most members voting to leave it on the market but recommending different changes in how it's prescribed.
A Food and Drug Administration committee delivered a split verdict on the diabetes drug Avandia on Wednesday, with most members voting to leave it on the market but recommending changes in how it's prescribed.
In a widely-anticipated ruling, a panel of experts will decide Wednesday whether or not to recommend that the FDA pull GlaxoSmithKline's blockbuster diabetes drug Avandia off the market in the United States.
A prominent Food and Drug Administration researcher sharply criticized a safety study by the manufacturer of the diabetes drug Avandia on Tuesday as an FDA panel weighed whether to yank the drug from the market.
The popular diabetes drug Avandia may be far more dangerous to patients than reported in a study touted by the drug's manufacturer, according to a strongly worded report posted Friday by the Food and Drug Administration.
A decade after critics first accused the Food and Drug Administration of downplaying side effects from Avandia, the agency says it will reveal on Friday the data it is reviewing ahead of an advisory panel meeting about the safety of the popular diabetes drug.
The diabetes drug Avandia is linked with tens of thousands of heart attacks, and drugmaker GlaxoSmithKline knew of the risks for years but worked to keep them from the public, a Senate committee report released Saturday says.
The diabetes drug Avandia is linked with tens of thousands of heart attacks, and drugmaker GlaxoSmithKline knew of the risks for years but worked to keep them from the public, according to a Senate committee report released Saturday.
CNN's Charles Hodson talks with GlaxoSmithKline CEO Jean-Pierre Garnier about his company's recent drop in earnings.
America's 20 million-plus diabetics mean dollar signs for drug companies that sell a slew of new products, including a successful drug based on the saliva of a Gila monster, and a failed inhalation device that's been compared to a "bong."
A study finds great differences between one generic drug and its brand-name counterpart. CNN's Dr. Sanjay Gupta reports.
Actos and Avandia have entered the spotlight again, as studies published in a leading medical journal pit the two diabetes drugs against each other by comparing their cardiovascular risks.
The FDA said on Tuesday that GlaxoSmithKline and Takeda agreed to strengthen heart failure warnings on their diabetes drugs, Avandia and Actos.
GlaxoSmithKline's stock rose nearly 4 percent on Tuesday, the day after FDA advisors voted to keep its diabetes drug Avandia on the market.
Food and Drug Administration panelists voted Monday that GlaxoSmithKline's diabetes drug Avandia should remain on the market, despite an analysis showing links to increased risk of heart attack.
GlaxoSmithKline Plc's widely used diabetes drug Avandia should be pulled off the market, Food and Drug Administration reviewer David Graham said in a presentation prepared for delivery Monday.
GlaxoSmithKline is getting ready for a face-to-face with the FDA about its diabetes drug Avandia, which has been on the hot seat since a study blamed the drug for increasing the risk of heart attack.
Debate over the heart attack risk associated with the GlaxoSmithKline diabetes drug Avandia took center stage Monday at the annual meeting of the American Diabetes Association.
Merck's new drug Januvia controls blood-sugar in two-thirds of diabetics when combined with the drug metformin, the company said Saturday.
The controversy surrounding GlaxoSmithKline's diabetes drug Avandia mounted Wednesday as a medical expert prepared to tell lawmakers the British drug maker threatened him with legal action when he first raised questions about the treatment's safety
GlaxoSmithKline PLC revealed Thursday that the U.S. Food and Drug Administration has declined to grant a priority review to its experimental cancer vaccine Cervarix
With concerns raised about heart risks of a popular diabetes drug, GlaxoSmithKline and the FDA scramble to respond
The recently published study results that link GlaxoSmithKline's blockbuster diabetes drug Avandia to heart attacks could shift market share to rivals Merck, Lilly and Amylin, despite questions surrounding the data, analysts say.
Two blockbuster diabetes drugs, Actos and Avandia, have locked horns for years in a very lucrative market but an impending shift in corporate partnerships and the introduction of new blockbusters could tilt the balance, industry analysts said.
© 2013 Cable News Network. Turner Broadcasting System, Inc. All Rights Reserved.
|